Search

Your search keyword '"Han, Jung Ho"' showing total 639 results
Start Over Author "Han, Jung Ho"
639 results on '"Han, Jung Ho"'

3. Central neurocytoma exhibits radial glial cell signatures with FGFR3 hypomethylation and overexpression

Author

Lee, Yeajina, Chowdhury, Tamrin, Kim, Sojin, Yu, Hyeon Jong, Kim, Kyung-Min, Kang, Ho, Kim, Min-Sung, Kim, Jin Wook, Kim, Yong-Hwy, Ji, So Young, Hwang, Kihwan, Han, Jung Ho, Hwang, Jinha, Yoo, Seong-Keun, Lee, Kyu Sang, Choe, Gheeyoung, Won, Jae-Kyung, Park, Sung-Hye, Lee, Yong Kyu, Shin, Joo Heon, Park, Chul-Kee, Kim, Chae-Yong, and Kim, Jong-Il

Published
2024
Full Text
View/download PDF

33. Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial

Author

Kim, Il Han, Park, Chul-Kee, Heo, Dae Seog, Kim, Chae-Yong, Rhee, Chang Hun, Nam, Do-Hyun, Lee, Seung Hoon, Han, Jung Ho, Lee, Se-Hoon, Kim, Tae Min, Kim, Dong-Wan, Kim, Jeong Eun, Paek, Sun Ha, Kim, Dong Gyu, Kim, In Ah, Kim, Yu Jung, Kim, Jee Hyun, Park, Byung-Joo, and Jung, Hee-Won

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Brain Cancer, Clinical Trials and Supportive Activities, Clinical Research, Patient Safety, Brain Disorders, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, 6.5 Radiotherapy and other non-invasive therapies, Adolescent, Adult, Aged, Antineoplastic Agents, Alkylating, Chemotherapy, Adjuvant, Combined Modality Therapy, Dacarbazine, Disease Progression, Female, Follow-Up Studies, Glioblastoma, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Prospective Studies, Temozolomide, Treatment Outcome, Young Adult, Neurosciences, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

A prospective randomized controlled multicenter phase III trial was conducted to evaluate the effects of neoadjuvant chemotherapy with nimustine (ACNU)-cisplatin (CDDP) when used in conjunction with radiotherapy plus adjuvant temozolomide in patients with newly diagnosed glioblastoma. The study population was randomly assigned into one treatment and one control group. Both groups received radiotherapy followed by six cycles of adjuvant oral temozolomide (150-200 mg/m(2)) for 5 days every 28 days after surgery. Prior to radiotherapy, the treatment group also received two cycles, 6 weeks apart, of neoadjuvant chemotherapy with ACNU (40 mg/m(2)/day) and CDDP (40 mg/m(2)/day) infused continuously for 72 h. The primary end-point was median survival time. The study has closed after interim analysis with a total of 82 patients (48.8% of target number) due to unacceptable high frequency of toxicity profiles in spite of the promising actuarial survival outcome. Median survival time was 28.4 months [90% confidence interval (CI), 21.1 months to not available] in the treatment group and 18.9 months (90% CI, 17.1-27.4 months) in the control group (P = 0.2). The 2-year survival rate and progression-free survival time were 50.9% and 6.6 months (90% CI, 3.5-9.5 months) in the treatment group and 27.8% and 5.1 months (90% CI, 3.8-8.8 months) in the control group. Grade 3 or 4 toxicity was documented in 26 (68.4%) patients in the treatment group, including three neutropenic fever and one death from sepsis, while grade 3 or 4 toxicity occurred in 6 patients (15.8%) in the control group. The high frequency of serious hematological toxicity with ACNU-CDDP neoadjuvant chemotherapy followed by radiotherapy and adjuvant temozolomide limits its usage as primary treatment for glioblastoma. Future studies should aim to identify a subpopulation at reduced risk for ACNU-CDDP toxicity so that the potential of this protocol can be realized.

Published
2011

34. Hearing Outcomes After Stereotactic Radiosurgery for Vestibular Schwannomas : Mechanism of Hearing Loss and How to Preserve Hearing

Author

Han, Jung Ho, Kim, Dong Gyu, Chung, Hyun-Tai, Paek, Sun Ha, Jung, Hee-Won, Schramm, Johannes, Series editor, Akalan, Nejat, Series editor, Benes, Vladimir, Series editor, Di Rocco, Concezio, Series editor, Lobo Antunes, J., Series editor, Pickard, John D., Series editor, Rappaport, Z. Harry, Series editor, and Sindou, Marc, Series editor

Published
2016
Full Text
View/download PDF

37. Cosmosiin Induces Apoptosis in Colorectal Cancer by Inhibiting PD-L1 Expression and Inducing ROS.

Author

Han, Jung Ho, Lee, Eun-Ji, Park, Wonyoung, Choi, Jang-Gi, Ha, Ki-Tae, and Chung, Hwan-Suck

Subjects
PROGRAMMED cell death 1 receptors, COLORECTAL cancer, PROGRAMMED death-ligand 1, IMMUNE checkpoint inhibitors, REACTIVE oxygen species, CANCER cells, APOPTOSIS
Abstract

Immunotherapies, particularly those concerning immune checkpoint inhibitors, have transformed cancer treatment in recent years. Programmed death-ligand 1 (PD-L1) is a key target for immunotherapy that is overexpressed in the cells of colorectal cancer, a widespread malignant cancer that poses a significant healthcare challenge. This study investigated the effects of cosmosiin treatment on colorectal cancer cell lines. Cosmosiin is a naturally occurring flavone glycoside compound that has potential health benefits, including antioxidant and immunomodulatory effects. This study showed that cosmosiin effectively suppresses the expression of PD-L1 and triggers apoptosis, which is facilitated through pathways that are related to reactive oxygen species. These outcomes suggest that cosmosiin could be a promising candidate for an immune checkpoint inhibitor in the treatment of colorectal cancer. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

48. The global burden of sudden infant death syndrome from 1990 to 2019: a systematic analysis from the Global Burden of Disease study 2019

Author

Park, Seoyeon, Han, Jung Ho, Hwang, Jimin, Yon, Dong Keon, Lee, Seung Won, Kim, Ji Hong, Koyanagi, Ai, Jacob, Louis, Oh, Hans, Kostev, Karel, Dragioti, Elena, Radua, Joaquim, Eun, Ho Seon, Shin, Jae Il, Smith, Lee, Park, Seoyeon, Han, Jung Ho, Hwang, Jimin, Yon, Dong Keon, Lee, Seung Won, Kim, Ji Hong, Koyanagi, Ai, Jacob, Louis, Oh, Hans, Kostev, Karel, Dragioti, Elena, Radua, Joaquim, Eun, Ho Seon, Shin, Jae Il, and Smith, Lee

Abstract

Background Sudden infant death syndrome (SIDS) still remains one of the leading causes of infant death worldwide, especially in high-income countries. To date, however, there is no detailed information on the global health burden of SIDS. Aims To characterize the global disease burden of SIDS and its trends from 1990 to 2019 and to compare the burden of SIDS according to the socio-demographic index (SDI). Design Systematic analysis based on the Global Burden of Disease (GBD) 2019 data. Methods Epidemiological data of 204 countries from 1990 to 2019 were collected via various methods including civil registration and vital statistics in the original GBD study. Estimates for mortality and disease burden of SIDS were modeled. Crude mortality and mortality rates per 100 000 population were analyzed. Disability-adjusted life years (DALYs) and DALY rates were also assessed. Results In 2019, mortality rate of SIDS accounted for 20.98 [95% Uncertainty Interval, 9.15-46.16] globally, which was a 51% decrease from 1990. SIDS was most prevalent in Western sub-Saharan Africa, High-income North America and Oceania in 2019. The burden of SIDS was higher in males than females consistently from 1990 to 2019. Higher SDI and income level was associated with lower burden of SIDS; furthermore, countries with higher SDI and income had greater decreases in SIDS burden from 1990 to 2019. Conclusions The burden of SIDS has decreased drastically from 1990 to 2019. However, the improvements have occurred disproportionately between regions and SDI levels. Focused preventive efforts in under-resourced populations are needed.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results